Search Results
Aug 11, 2025, 08:45 ET The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd.(BHVN) Shareholders
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 11, 2025, 07:00 ET Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
study expected to initiate in 2H 2025.Phase 1 studies in healthy volunteers with BHV-1400 and BHV-1600 concluding, with BHV-1400 Phase 1 studies expanding to include patients with IgA nephropathy. BHV-1400 potentially registrational study expected to initiate in 2026.Four additional
More news about: Biohaven Ltd.
Aug 11, 2025, 04:10 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class
More news about: The Schall Law Firm
Aug 08, 2025, 09:40 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Faruqi & Faruqi, LLP
Aug 08, 2025, 08:45 ET Shareholders that lost money on Biohaven Ltd.(BHVN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 07, 2025, 08:45 ET Biohaven Ltd. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 12, 2025 to Discuss Your Rights - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Aug 05, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Glancy Prongay & Murray LLP
Aug 05, 2025, 08:45 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd.(BHVN) Shareholders
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Aug 05, 2025, 03:51 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Aug 04, 2025, 08:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Aug 01, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Law Offices of Howard G. Smith
Aug 01, 2025, 09:00 ET Shareholders that lost money on Biohaven Ltd.(BHVN) should contact Levi & Korsinsky about pending Class Action - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Jul 31, 2025, 17:38 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Jul 31, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Jul 31, 2025, 08:45 ET The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd.(BHVN) Shareholders
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm
Jul 29, 2025, 10:22 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: Faruqi & Faruqi, LLP
Jul 29, 2025, 08:45 ET Shareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Jul 28, 2025, 12:00 ET Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 28, 2025, 09:44 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
market. Biohaven overstated the regulatory prospects of its drug candidate troriluzole as a treatment for SCA. The Company also overstated the efficacy of BHV-7000 as a treatment for bipolar disorder. Based on these facts, the Company's public statements were false and materially misleading throughout the class
More news about: The Schall Law Firm
Jul 28, 2025, 08:45 ET BHVN LAWSUIT ALERT: The Gross Law Firm Notifies Biohaven Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Gross Law Firm
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
is developing, among other product candidates, troriluzole for the treatment of spinocerebellar ataxia ("SCA"), among other indications, as well as BHV-7000 for the treatment of bipolar disorder, among other indications. In May 2022, a Phase 3 trial evaluating troriluzole's
More news about: Pomerantz LLP
Jul 26, 2025, 11:12 ET BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Jul 25, 2025, 08:45 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd.(BHVN) Shareholders
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Jul 24, 2025, 08:45 ET Shareholders of Biohaven Ltd. Should Contact The Gross Law Firm Before September 12, 2025 to Discuss Your Rights - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm